Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

NCT03480022 on ClinicalTrials.gov · last registry update 2021-06-07

A small phase 3 — 88 participants, against a typical 424. The sponsor logged completion for 22 February 2021. Primary outcome, as filed: Absolute Body Weight (BW). liraglutide is approved in the US, but not for pcos and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Woman's
Sponsor type: Other
Enrollment: 88
Started: 2018-09-26
Primary completion: 2021-02-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Absolute Body Weight (BW)

Conditions studied

Pre Diabetes · Polycystic Ovary Syndrome · Obesity Android

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.